Korro Bio Inc (KRRO)

Nov 21, 2024, 4:01 PM EST - 2 months ago

Korro to Participate in Upcoming Investor Conferences

Nov 21, 2024, 7:30 AM EST - 2 months ago

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Nov 14, 2024, 8:00 AM EST - 2 months ago

Korro to Present at the Jefferies London Healthcare Conference

Nov 4, 2024, 7:25 AM EST - 2 months ago

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

Sep 30, 2024, 8:00 AM EDT - 3 months ago

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Aug 27, 2024, 8:00 AM EDT - 5 months ago

Korro to Participate in Upcoming September Investor and Scientific Conferences

Aug 13, 2024, 4:01 PM EDT - 5 months ago

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates

May 30, 2024, 4:01 PM EDT - 8 months ago

Korro to Participate in Upcoming June Investor and Scientific Conferences

May 20, 2024, 2:30 PM EDT - 8 months ago

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

May 14, 2024, 4:01 PM EDT - 8 months ago

Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

Apr 18, 2024, 8:30 AM EDT - 9 months ago

Korro Announces $70 Million Private Placement

Mar 26, 2024, 4:01 PM EDT - 10 months ago

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

Mar 14, 2024, 5:34 PM EDT - 11 months ago

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

KRYS MREO TAK WVE

Feb 27, 2024, 8:00 AM EST - 11 months ago

Korro to Present at the TD Cowen 44th Annual Health Care Conference

Jan 18, 2024, 8:00 AM EST - 1 year ago

Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

Jan 4, 2024, 8:00 AM EST - 1 year ago

Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 7, 2023, 8:00 AM EST - 1 year ago

Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Nov 28, 2023, 8:00 AM EST - 1 year ago

Korro Bio Appoints Dr. Rachel Meyers to Board of Directors

Nov 3, 2023, 3:31 PM EDT - 1 year ago

UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Nov 3, 2023, 12:19 PM EDT - 1 year ago

Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Oct 6, 2023, 2:14 PM EDT - 1 year ago

FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ

Aug 10, 2023, 4:01 PM EDT - 1 year ago

Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results

Jul 14, 2023, 6:30 AM EDT - 1 year ago

Korro Bio and Frequency Therapeutics Announce Merger Agreement

May 12, 2023, 4:01 PM EDT - 1 year ago

Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results

Mar 10, 2023, 7:30 AM EST - 2 years ago

Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results

Feb 27, 2023, 7:30 AM EST - 2 years ago

Frequency Therapeutics to Participate at Upcoming March Investor Conferences

Feb 23, 2023, 7:45 AM EST - 2 years ago

Small Animal Imaging In Vivo Market is Anticipated to Reach a Value of USD 6.1 Billion by Growing at a CAGR of 8.89% During 2022-2028; Expanding Healthcare Sector and Rising Clinical Research to Elevate Market Growth

Feb 13, 2023, 8:05 AM EST - 2 years ago

Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Dec 19, 2022, 7:30 AM EST - 2 years ago

Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program

Dec 15, 2022, 7:30 AM EST - 2 years ago

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company's Second Therapeutic Candidate for Sensorineural Hearing Loss

Nov 17, 2022, 7:30 AM EST - 2 years ago

Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results

Nov 8, 2022, 4:05 PM EST - 2 years ago

Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results

Oct 12, 2022, 7:30 AM EDT - 2 years ago

Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Aug 30, 2022, 7:30 AM EDT - 2 years ago

Frequency Therapeutics to Participate in September Investor and Medical Conferences

Aug 9, 2022, 4:05 PM EDT - 2 years ago

Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results

May 18, 2022, 7:30 AM EDT - 2 years ago

Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference

May 4, 2022, 4:30 PM EDT - 2 years ago

Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results

Apr 22, 2022, 7:30 AM EDT - 2 years ago

Frequency Therapeutics to Participate in B. Riley Securities' Neuro & Ophthalmology Investor Conference

Mar 15, 2022, 7:30 AM EDT - 3 years ago

Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results

Feb 28, 2022, 7:30 AM EST - 3 years ago

Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences

Jan 4, 2022, 7:30 AM EST - 3 years ago

Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference

Dec 9, 2021, 1:18 PM EST - 3 years ago

Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise

Dec 9, 2021, 7:30 AM EST - 3 years ago

Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise

Nov 15, 2021, 7:30 AM EST - 3 years ago

Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results

Nov 9, 2021, 10:19 AM EST - 3 years ago

Frequency Therapeutics redesigns study after disappointing Phase 2 results, debuts new hearing loss and MS drugs

Nov 9, 2021, 7:30 AM EST - 3 years ago

Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis

Oct 27, 2021, 7:30 AM EDT - 3 years ago

Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program